Skip to content

Prospective Study to Validate Ablation Parameters with MRI Based Scar for Left Atrial Ablation

Prospective Study to Validate Ablation Parameters with MRI Based Scar for Left Atrial Ablation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04363307
Enrollment
64
Registered
2020-04-27
Start date
2020-05-14
Completion date
2023-07-31
Last updated
2024-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation, Ablation

Brief summary

One of the goals of an ablation procedure is to create scarring of cardiac tissue. Not all ablations result in scar tissue. Advances in technology have improved scarring but ideal parameters that result in scar tissue are still not completely clear and there is great variability in the parameters used. Theoretically, intense ablation can always create scar tissue but is also likely to create more complications such as cardiac perforations. The investigator recently published another retrospective study looking at ablation parameters that reliably result in scar tissue but it had its limitations as it was retrospectively done. This is a prospective study to validate the parameters that result in long term scarring. MRI has long been used to visualize ablation scar tissue. So in this study patients undergoing, initial left atrial ablation for atrial fibrillation as standard of care will undergo a 3 month post ablation MRI and that will be used to validate the ablation parameters.

Detailed description

A critical step to improve atrial fibrillation (AF) ablation broadly is to minimize interoperator variability. VISITAG SURPOINT calculated a marker tag index value by combining contact force, power setting, and duration of energy delivered. Use of VISITAG SURPOINT has accurately predicted sites of pulmonary vein reconnection and regional changes in late gadolinium enhancement (LGE) and T2 (edema) intensity 24 hours post ablation. Prospective use of the ablation index improves first pass pulmonary vein isolation and 1-year freedom from atrial tachyarrhythmias compared to conventional treatment. There remains a paucity of data regarding if ablation guided by index values and VISITAG SURPOINT results in durable scar formation in humans in general and compared to conventional approaches. In addition, the relative contribution of the components of VISITAG SURPOINT impact scar formation in-vivo and across a broad diversity of atrial anatomies. Such data are critical in patients that present with various degrees of atrial myopathies, arrhythmia substrate, and anatomies.

Interventions

Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT

DEVICEMRI

Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation

Sponsors

Biosense Webster, Inc.
CollaboratorINDUSTRY
Ravi Ranjan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Paroxysmal or early Persistent AF (continuous AF duration less than 3 months and CHADSVASC great than or equal to 2). * First time ablation for AF * Agreeable to a 3 month MRI

Exclusion criteria

* Claustrophobic (unable to undergo MRI) * Having undergone prior left atrial ablation including AT or atypical flutter * Metal implants that preclude getting an MRI * eGFR \< 30

Design outcomes

Primary

MeasureTime frame
Correlation of ablative force with scar formation, on a scale of 0 (no correlation) to 1 (total correlation)3 months
Correlation of ablative power with scar formation, on a scale of 0 (no correlation) to 1 (total correlation)3 months
Correlation of ablation time on scar formation, on a scale of 0 (no correlation) to 1 (total correlation)3 months

Secondary

MeasureTime frame
Change in circumferential extent of the lesion around pulmonary veins after ablation as measured by scar area3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026